Piramal Pharma Q2 Results Live : Piramal Pharma declared their Q2 results on 23 Oct, 2024, showcasing robust financial performance. The company’s topline saw a significant increase of 17.28% year-over-year, while profits skyrocketed by an impressive 350% during the same period.
In comparison to the previous quarter, Piramal Pharma’s revenue grew by 14.89%, and profit surged by 125.49%. This quarter’s results are a testament to the company’s effective operational strategies and market positioning.
Notably, the Selling, General & Administrative (SG&A) expenses saw a decline of 3.48% quarter-over-quarter, although they increased by 8.43% year-over-year, reflecting the company’s focus on cost management amidst growth.
Operating income also witnessed a commendable rise, up by 41.83% sequentially and 21.27% year-over-year, indicating a solid operational performance. The Earnings Per Share (EPS) for Q2 stood at ₹0.17, which marks a remarkable increase of 325% year-over-year.
Despite a slight dip of -6.19% in the last week, Piramal Pharma has delivered a staggering return of 57.11% over the last six months and 57% year-to-date. Currently, the company’s market cap stands at ₹28,770.91 Cr, with a 52-week high of ₹243.99 and a low of ₹87.5.
As of 24 Oct, 2024, the outlook for Piramal Pharma appears optimistic, with 3 out of 5 analysts giving a Buy rating and 2 analysts recommending a Strong Buy. The consensus recommendation remains a Strong Buy, reflecting confidence in the company’s future performance.
Piramal Pharma Financials
Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
---|---|---|---|---|---|
Total Revenue | 2241.75 | 1951.14 | +14.89% | 1911.38 | +17.28% |
Selling/ General/ Admin Expenses Total | 559.53 | 579.69 | -3.48% | 516.03 | +8.43% |
Depreciation/ Amortization | 192.22 | 184.55 | +4.16% | 184.51 | +4.18% |
Total Operating Expense | 1487.11 | 1419.07 | +4.79% | 1289.08 | +15.36% |
Operating Income | 754.64 | 532.07 | +41.83% | 622.3 | +21.27% |
Net Income Before Taxes | 120.12 | -45.08 | +366.46% | 39.56 | +203.64% |
Net Income | 22.59 | -88.64 | +125.49% | 5.02 | +350% |
Diluted Normalized EPS | 0.17 | -0.67 | +125.37% | 0.04 | +325% |
Leave a Reply